HGEN News and Press, Humanigen Inc. From 04/19/21

Humanigen ([[HGEN]] -2.8%) announced positive data from the Phase 1b portion of the ZUMA-19 trial which involved six patients in two cohorts.The study was designed to evaluate the efficacy and safety of Lenzilumab with CAR-T in diffuse large B-cell lymphoma (DLBCL). The overall ORR ...

At the recommended Phase 2 dose, lenzilumab in combination with CAR-T, demonstrated a 100% objective response rate (ORR) and no severe cytokine release syndrome or severe neurotoxicity Lenzilumab reduced IL-6, CRP, ferritin, MCP-1, IL-8, and IP-10 (CXCL-10) among others Humani...

Calling the results positive, Humanigen (HGEN) says that the data from a Phase 1 study evaluating Ifabotuzumab in patients with glioblastoma multiforme (“GBM”) will be presented at the AACR Annual Meeting 2021 which is scheduled to start tomorrow.Designed to determine the s...

Phase 1 dose escalation and bioimaging study shows that ifabotuzumab demonstrates highly specific tumor targeting in patients with recurrent glioblastoma multiforme Results to be presented as a virtual poster at American Association for Cancer Research (AACR) 2021 Annual Meeting ...

Humanigen (NASDAQ: HGEN) recently announced impressive results from a late-stage study of its COVID-19 antibody therapy lenzilumab. The biotech stock skyrocketed on the news but subsequently gave up some of its gains. In this Motley Fool Live video recorded on March 31 ...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The holiday-shortened week saw tech suddenly back in favor after a first quarter where cyclical and value plays dominated. The Nasdaq, which ...

Shares of clinical-stage biopharmaceutical company Humanigen (NASDAQ: HGEN) were falling sharply on Wednesday following the company's announcement of the pricing of a public offering of common stock. Naturally, investors aren't thrilled with the prospect of Humanigen diluting its sh...

Gainers: Wah Fu Education (WAFU) +74%.Liquid Media (YVR) +25%.Conn's (CONN) +23%.FreightCar America (RAIL) +23%.Greenlane (GNLN) +22%.Arcadia Biosciences (RKDA) +20%.SunLink Health Systems (SSY) +19%.Sunworks (SUNW) +18%.Scienjoy (SJ) +18%.Chargepoint (CHPT) +16%.Losers: V...

Gainers: Greenlane (GNLN) +37%, SunLink Health Systems (SSY) +17%, Aquestive Therapeutics (AQST) +14%, Evolus (EOLS) +14%, Spectrum Pharmaceuticals (SPPI) +11%.Losers: 9 Meters Biopharma (NMTR) -22%, Delcath Systems (DCTH) -20%, Celsion (CLSN)...

Humanigen (HGEN) has priced its public offering of 5M common shares at 18.50/share, resulting in gross proceeds of ~$92.5M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used for manufacturing and commercial preparation of COVID-19 candidate lenzilumab in the ...